Following the UK-wide National Patient Safety Alert issued on 29 July 2025, the supply situation for antimicrobial medicines used to treat TB has significantly improved. Please note that this MSAN supersedes the noted National Patient Safety Alert (NatPSA). 

UK licensed packs of rifampicin 150mg capsules, rifampicin 600mg IV vials, and Rifinah® 300 (rifampicin 300mg / isoniazid 150mg) tablets remain constrained and will be available intermittently. 

Unlicensed imports of Rifampicin 150mg capsules, rifampicin 600mg IV vials, and Rifinah® 300 (rifampicin 300mg / isoniazid 150mg) tablets have been sourced in sufficient quantities to meet gap in supply of licensed packs; however, lead times may vary. 

Licensed stock of other TB treatments is now available. To ensure fair distribution of licensed stock, monthly allocations will be implemented across the UK for specific TB medicines as they become available. Allocation details will be shared directly with Health Boards via NSS National Procurement. 

For full information on stock levels, allocations, importer details, and expected resupply dates, please refer to the Medicines Supply Tool (registration required – see paragraph 17 for details on how to register). 

Normal services can now resume, including latent TB screening / treatment and, where needed, the prescribing of rifampicin capsules for non-TB indications in both primary and secondary care. Utilisation of available licensed stock and unlicensed imports should be optimised to ensure continuity of patient treatment.